Use: Labeled indications
- INDICATIONS AND USAGE Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
Full indications and usage US FDA label
INDICATIONS AND USAGE Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors.
Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy.
Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary.
There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief.
In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate.
Contraindications
CONTRAINDICATIONS Hydrochlorothiazide is contraindicated in patients with anuria. Hypersensitivity to this product or other sulfonamide derived drugs is also contraindicated.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION For Control of Hypertension: The adult initial dose of hydrochlorothiazide is one capsule given once daily whether given alone or in combination with other antihypertensives. Total daily doses greater than 50 mg are not recommended.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Dosage forms
Philippines
- Tablet: 12.5 mg, 25 mg, 50 mg
- Film-coated tablet: 12.5 mg, 25 mg
Registered products in the Philippines
27 products registered with the Food and Drug Administration (FDA) Philippines list Hydrochlorothiazide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products27
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ChlortazidHydrochlorothiazide | 50 mg TabletAlu/ Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-5313 | May 9, 2029 | |
Clozid-12.5Hydrochlorothiazide | 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | Ambica International Corporation | DRP-4958 | Feb 26, 2032 | |
Clozid-25Hydrochlorothiazide | 25 mg Tablet | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | Ambica International Corporation | DRP-6010 | Feb 18, 2032 | |
CotrazidHydrochlorothiazide | 25 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY15472 | Jul 11, 2028 | |
DiachlorozHydrochlorothiazide | 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4958-01 | Feb 26, 2032 | |
DiozideHydrochlorothiazide | 25 mg Film-Coated TabletAlu-Clear PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Concept Pharmaceuticals Ltd.India | Phil Pharmawealth, Inc. | DR-XY43707 | Sep 9, 2029 | |
DiucareHydrochlorothiazide | 12.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY33197 | Apr 12, 2027 | |
DiucareHydrochlorothiazide | 12.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, IncPhilippines | Trader: TotalCare Pharma Inc. | DRP-15126 | Apr 12, 2027 | |
DiucareHydrochlorothiazide | 25 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY33196 | Apr 12, 2027 | |
DiucareHydrochlorothiazide | 25 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-15316 | Apr 12, 2027 | |
DiuzidHydrochlorothiazide | 12.5 mg TabletBlister pack x 10's (Box of 100's | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DR-XY33803 | Sep 13, 2027 | |
DiuzidHydrochlorothiazide | 12.5 mg TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DRP-17161 | Sep 13, 2027 | |
DiuzidHydrochlorothiazide | 25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | New Willore Pharma Corp. | DRP-17160 | Nov 13, 2031 | |
HizidHydrochlorothiazide | 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cooper Pharma Ltd.India | Ambica International Corporation | DRP-4715 | Sep 16, 2028 | |
HydraxHydrochlorothiazide | 12.5 mg Film-Coated TabletAluminum foil strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY33464 | Jun 7, 2027 | |
HydromelHydrochlorothiazide | 50 mg TabletAlu/ Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Amiel Trading Inc. | DRP-5313-03 | May 9, 2029 | |
HydropelHydrochlorothiazide | 50 mg TabletAlu/ Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-5313-02 | May 9, 2029 | |
HyklorHydrochlorothiazide | 50 mg TabletAlu Clear/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Endure Medical, Inc. | DR-XY45313 | Apr 20, 2031 | |
HytazHydrochlorothiazide | 12.5 Film-Coated TabletFlex Foil Strip x 10's (Box of 200s) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-9978 | Dec 12, 2027 | |
HytazHydrochlorothiazide | 25 mg Film-Coated TabletFlex Foil Strip x 10's Box of 200s | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-9982 | Dec 12, 2027 | |
KOTRAZIDHydrochlorothiazide | 50 mg TabletAlu/Clear PVC Blister Pack x 20's Box of 100's | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-5313-01 | May 9, 2029 | |
NoneHydrochlorothiazide | 12.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-4958-02 | Feb 26, 2032 | |
NoneHydrochlorothiazide | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cooper Pharma LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4714 | Sep 16, 2028 | |
NoneHydrochlorothiazide | 25 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-6010-01 | Feb 18, 2032 | |
NoneHydrochlorothiazide | 25mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-7079 | Oct 19, 2028 | |
UrilzidHydrochlorothiazide | 12.5 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Metro Manila | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1215 | Feb 27, 2032 | |
UrilzidHydrochlorothiazide | 25 mg Film-Coated TabletAluminum Foil Strip Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DR-XY34309 | Feb 27, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Acute Myopia and Secondary Angle-Closure Glaucoma: Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.
Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Diabetes and Hypoglycemia: Latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. Renal Disease: Cumulative effects of the thiazides may develop in patients with impaired renal function. In such patients, thiazides may precipitate azotemia.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions: When given concurrently the following drugs may interact with thiazide diuretics: Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. Antidiabetic drugs - (oral agents and insulin) dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or potentiation.
Cholestyramine and colestipol resins - Cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroid, ACTH – intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use.
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant. Lithium - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with hydrochlorothiazide.
Non-steroidal anti-inflammatory drugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. When hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patients should be observed closely to determine if the desired effect of the diuretic is obtained.
Drug/Laboratory Test Interactions - Thiazides should be discontinued before carrying out tests for parathyroid function (see PRECAUTIONS, General). Carcinogenesis, Mutagenesis, Impairment of Fertility: Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of approximately 100 mg/kg/day).
The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice. Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of Salmonella typhimurium strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene.
Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1,300 mcg/mL, and in the Aspergillus nidulans non-disjunction assay at an unspecified concentration. Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The adverse reactions associated with hydrochlorothiazide have been shown to be dose related. In controlled clinical trials, the adverse events reported with doses of 12.5 mg hydrochlorothiazide once daily were comparable to placebo. The following adverse reactions have been reported for doses of hydrochlorothiazide 25 mg and greater and, within each category, are listed in the order of decreasing severity.
Body as a whole: Weakness. Cardiovascular: Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia.
Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. Metabolic: Electrolyte imbalance (see PRECAUTIONS), hyperglycemia, glycosuria, hyperuricemia.
Musculoskeletal: Muscle spasm. Nervous System/Psychiatric: Vertigo, paresthesia, dizziness, headache, restlessness. Renal: Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS). Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia.
Special Senses: Transient blurred vision, xanthopsia. Urogenital: Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn. Postmarketing Experience: The following adverse reaction has been identified during post-approval use of hydrochlorothiazide. Because the reaction is reported voluntarily from a population of uncertain size, it is not possible to reliably estimate the frequency or establish a causal relationship to drug exposure.
Non-melanoma Skin Cancer: Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy: Teratogenic Effects: Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3,000 and 1,000 mg hydrochlorothiazide/kg, respectively, provided no evidence of harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nonteratogenic Effects: Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.
Nursing Mothers: Thiazides are excreted in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue hydrochlorothiazide, taking into account the importance of the drug to the mother.
Pharmacodynamics
Pharmacodynamics (US label) US FDA label
Pharmacodynamics: Acute antihypertensive effects of thiazides are thought to result from a reduction in blood volume and cardiac output, secondary to a natriuretic effect, although a direct vasodilatory mechanism has also been proposed. With chronic administration, plasma volume returns toward normal, but peripheral vascular resistance is decreased.
The exact mechanism of the antihypertensive effect of hydrochlorothiazide is not known. Thiazides do not affect normal blood pressure. Onset of action occurs within 2 hours of dosing, peak effect is observed at about 4 hours, and activity persists for up to 24 hours.
Pharmacokinetics
The plasma elimination half-life has been reported to be 6 to 15 hours.
Following oral doses of 12.5 to 100 mg, 55% to 77% of the administered dose appears in urine and greater than 95% of the absorbed dose is excreted in urine as unchanged drug.
In patients with renal disease, plasma concentrations of hydrochlorothiazide are increased and the elimination half-life is prolonged.
Pharmacokinetics (US label) US FDA label
Pharmacokinetics and Metabolism: Hydrochlorothiazide is well absorbed (65% to 75%) following oral administration. Absorption of hydrochlorothiazide is reduced in patients with congestive heart failure. Peak plasma concentrations are observed within 1 to 5 hours of dosing and range from 70 to 490 ng/mL following oral doses of 12.5 to 100 mg.
Plasma concentrations are linearly related to the administered dose. Concentrations of hydrochlorothiazide are 1.6 to 1.8 times higher in whole blood than in plasma. Binding to serum proteins has been reported to be approximately 40% to 68%. The plasma elimination half-life has been reported to be 6 to 15 hours. Hydrochlorothiazide is eliminated primarily by renal pathways.
Following oral doses of 12.5 to 100 mg, 55% to 77% of the administered dose appears in urine and greater than 95% of the absorbed dose is excreted in urine as unchanged drug. In patients with renal disease, plasma concentrations of hydrochlorothiazide are increased and the elimination half-life is prolonged. When hydrochlorothiazide is administered with food, its bioavailability is reduced by 10%, the maximum plasma concentration is reduced by 20%, and the time to maximum concentration increases from 1.6 to 2.9 hours.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Hydrochlorothiazide 25 mg Tablet | ₱2.95–₱3.15Reference ₱2.95 | per tablet | DPRI procurement range |
| 12.5 mg tablet | ₱3.50 | per tablet | PhilHealth GAMOT fixed fee |
| 25 mg tablet | ₱4.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Hydrochlorothiazide |
| PNF listing | Oral: 12.5 mg and 25 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Hydrochlorothiazide · Actavis Pharma, Inc. [US FDA-approved label, version 25, December 31, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3eb7294-f913-434b-896c-da028bfebc73
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .